At CTS, we understand the impact converting to the Ortho viral marker platform has on your operations. As we get closer to our implementation date of January 11, 2021 we are committed to providing you information as it becomes available.
Package inserts for the new assays are now available. You can review them on the Communications page by clicking this link: Communications,
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...